Karyopharm Therapeutics Inc. Q2 2025 Earnings Recap

KPTI Q2 2025 August 11, 2025

Get alerts when KPTI reports next quarter

Karyopharm Therapeutics delivered solid Q2 2025 results, driven by strong commercial performance and significant progress in pivotal Phase III trials, positioning the company for potential transformative outcomes in myelofibrosis and endometrial cancer.

Earnings Per Share Miss

$-4.32 vs $-3.80 est.

-13.7% surprise

Revenue Miss

37929000 vs 39562330 est.

-4.1% surprise

Market Reaction

1-Day +6.63%

5-Day +48.28%

30-Day +76.13%

See KPTI alongside your other holdings

Add to your portfolio — free

Key Takeaways

Successfully completed enrollment in the Phase III SENTRY trial for myelofibrosis, marking a key milestone in the drug development timeline.
Positive preliminary safety data for the selinexor and ruxolitinib combination suggests enhanced tolerability compared to ruxolitinib alone.
Anticipation for top-line results in March 2026, with potential peak revenue estimates of $1 billion annually for selinexor in myelofibrosis in the U.S. market.
Continued engagement with lenders to enhance liquidity amidst financial constraints, underscoring efforts to maintain operational stability.

This summary was generated by AI from the official earnings call transcript and is provided for informational purposes only. It does not constitute financial advice. For the complete transcript and financial data, visit KPTI on AllInvestView.

Next Q3 2025